| Literature DB >> 27222823 |
C Boix1, M Ibáñez1, D Fabregat-Safont1, E Morales2, L Pastor2, J V Sancho1, J E Sánchez-Ramírez2, F Hernández1.
Abstract
In this work, two analytical methodologies based on liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) were developed for quantification of emerging pollutants identified in sewage sludge after a previous wide-scope screening. The target list included 13 emerging contaminants (EC): thiabendazole, acesulfame, fenofibric acid, valsartan, irbesartan, salicylic acid, diclofenac, carbamazepine, 4-aminoantipyrine (4-AA), 4-acetyl aminoantipyrine (4-AAA), 4-formyl aminoantipyrine (4-FAA), venlafaxine and benzoylecgonine. The aqueous and solid phases of the sewage sludge were analyzed making use of Solid-Phase Extraction (SPE) and UltraSonic Extraction (USE) for sample treatment, respectively. The methods were validated at three concentration levels: 0.2, 2 and 20 μg L(-1) for the aqueous phase, and 50, 500 and 2000 μg kg(-1) for the solid phase of the sludge. In general, the method was satisfactorily validated, showing good recoveries (70-120%) and precision (RSD < 20%). Regarding the limit of quantification (LOQ), it was below 0.1 μg L(-1) in the aqueous phase and below 50 μg kg(-1) in the solid phase for the majority of the analytes. The method applicability was tested by analysis of samples from a wider study on degradation of emerging pollutants in sewage sludge under anaerobic digestion. The key benefits of these methodologies are: • SPE and USE are appropriate sample procedures to extract selected emerging contaminants from the aqueous phase of the sewage sludge and the solid residue. • LC-MS/MS is highly suitable for determining emerging contaminants in both sludge phases. • Up to our knowledge, the main metabolites of dipyrone had not been studied before in sewage sludge.Entities:
Keywords: Emerging contaminants; Quantification of selected emerging compounds in liquid and solid phases of the sewage sludge by LC–MS/MS; liquid chromatography; sewage sludge; solid-phase extraction; tandem mass spectrometry; ultrasonic-assisted extraction
Year: 2016 PMID: 27222823 PMCID: PMC4865632 DOI: 10.1016/j.mex.2016.04.010
Source DB: PubMed Journal: MethodsX ISSN: 2215-0161
MS/MS optimized conditions for selected compounds.
| Compound | ESI | RT | Cone | Q | CE | q | CE |
|---|---|---|---|---|---|---|---|
| 4-AA | + | 3.91 | 20 | 204.4 > 83.1 | 15 | 204.4 > 159.1 | 10 |
| 4-AAA | + | 4.58 | 20 | 246.3 > 228.3 | 20 | 246.3 > 83.1 | 20 |
| 4-FAA | + | 4.55 | 20 | 232.2 > 83.1 | 20 | 232.2 > 104.1 | 20 |
| Acesulfame | – | 6.32 | 20 | 162.2 > 82.0 | 15 | 162.2 > 77.9 | 30 |
| BE | + | 5.26 | 30 | 290.2 > 168.2 | 20 | 290.2 > 105.1 | 30 |
| Carbamazepine | + | 7.13 | 30 | 237.3 > 194.4 | 20 | 237.3 > 192.4 | 45 |
| Diclofenac | + | 8.51 | 20 | 296.2 > 214.2 | 30 | 296.2 > 278.1 | 10 |
| Fenofibric Acid | – | 8.71 | 20 | 317.2 > 231.2 | 20 | 317.2 > 195.3 | 35 |
| Irbesartan | + | 7.98 | 30 | 429.3 > 207.4 | 25 | 429.3 > 195.4 | 20 |
| Salicylic Acid | – | 7.50 | 20 | 137.1 > 93.1 | 15 | 137.1 > 65.0 | 25 |
| Thiabendazole | + | 4.80 | 40 | 202.3 > 175.2 | 25 | 202.3 > 131.2 | 30 |
| Valsartan | + | 8.21 | 20 | 436.2 > 235.3 | 20 | 436.2 > 207.2 | 25 |
| Venlafaxine | + | 5.08 | 20 | 278.4 > 57.8 | 15 | 278.4 > 260.4 | 10 |
| BE-d3 | + | 5.26 | 30 | 293.3 > 171.2 | 20 | ||
| Diclofenac-d4 | + | 8.51 | 20 | 300.1 > 219.2 | 20 | ||
| Irbesartan-d6 | + | 7.98 | 30 | 435.3 > 213.4 | 25 | ||
| Salicylic Acid-d4 | – | 7.50 | 20 | 141.1 > 97.1 | 15 | ||
| Thiabendazole-d6 | + | 4.80 | 40 | 208.3 > 136.0 | 30 | ||
| Valsartan-d8 | + | 8.21 | 20 | 444.3 > 291.2 | 20 | ||
| Venlafaxine-d6 | + | 5.08 | 20 | 284.3 > 63.9 | 15 |
ESI: electrospray ionization; RT: retention time; Q: quantification transition; q: confirmation transition; CE: collision energy.
Results of the validation for aqueous and solid phases of sewage sludge. Limit of quantification (LOQ), recovery (%) and relative standard deviation (RSD) at the three validation levels tested.
| Compound | Aqueous Phase (n = 3) | Solid Phase (n = 3) | ILIS | r | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| % Recovery (RSD) | LOQ | % Recovery (RSD) | LOQ | ||||||||
| 0.2 μg L−1 | 2 μg L−1 | 20 μg L−1 | 50 μg kg−1 | 500 μg kg−1 | 2000 μg kg−1 | ||||||
| 4-AA | n.v. | 37 (19) | 27 (9) | 99 | n.v. | 23 (23) | 20 (21) | 11 | BE-d3 | 0.993 | (0.5–100) |
| 4-AAA | n.v. | 106 (20) | 93 (6) | 33 | 76 (4) | 110 (24) | 92 (21) | 46 | BE-d3 | 0.999 | (0.1–50) |
| 4-FAA | n.v. | 101 (16) | 99 (5) | 96 | 97 (16) | 105 (23) | 111 (14) | 46 | BE-d3 | 0.999 | (0.1–50) |
| BE | 103 (10) | 96 (3) | 94 (2) | 9.3 | 88 (10) | 86 (15) | 90 (8) | 15 | BE-d3 | 0.999 | (0.05−500) |
| Carbamazepine | 88 (23) | 92 (21) | 116 (8) | 8.6 | 114 (11) | 114 (13) | 117 (14) | 5.4 | Irbesartan-d6 | 0.999 | (0.05−500) |
| Diclofenac | n.v. | 96 (1) | 99 (24) | 48 | n.v. | 114 (15) | 98 (7) | 63 | Diclofenac-d4 | 0.999 | (0.05−500) |
| Irbesartan | 107 (7) | 98 (3) | 103 (9) | 14 | 80 (12) | 90 (9) | 97 (14) | 1.2 | Irbesartan-d6 | 0.999 | (0.1–500) |
| Salicylic Acid | n.v. | n.v. | 95 (22) | 220 | n.v. | n.v. | 109 (17) | 35 | Salicylic Acid-d4 | 0.995 | (0.05−500) |
| Thiabendazole | n.v. | n.v. | 114 (42) | 84 | n.v. | 122 (1) | 92 (11) | 17 | Thiabendazole-d6 | 0.999 | (0.5–500) |
| Valsartan | n.v. | 105 (6) | 100 (4) | 74 | 66 (8) | 76 (22) | 100 (20) | 27 | Valsartan-d8 | 0.998 | (0.25–500) |
| Venlafaxine | 98 (21) | 96 (2) | 107 (6) | 0.2 | 82 (24) | 91 (15) | 92 (19) | 7.5 | Venlafaxine-d6 | 0.999 | (0.1–500) |
n.v.: These compounds could not be validated as all the three samples used as “blank” contained high analyte concentration.
Validation performed for n = 2, due to the high analyte concentration found in one of the three “blank” samples used for validation.
Fig. 1LC–MS/MS chromatograms for compounds at the lowest level validated (50 μg kg−1) in the solid phase of the sludge.
Fig. 2LC–MS/MS chromatograms for compounds at the lowest level validated (50 μg kg−1) in the solid phase of the sludge.